FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

     (Mark One)
          X      Quarterly Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


                      For Quarter Ended: November 30, 2000

                                       OR
          _      Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                Georgia                                   22-2408354
      (State or other jurisdiction of                  (I.R.S. Employer
       incorporation or organization)                 Identification No.)

         3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091-5625
         (Address of principal executive offices)           (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of January 10, 2001: Common Stock, $. 10 Par Value - 7,277,617

<PAGE>
<TABLE>
                                                          IMMUCOR, INC.
                                               Condensed Consolidated Balance Sheets
<CAPTION>

                                                                                   November 30, 2000            May 31, 2000
ASSETS                                                                                (Unaudited)                 (Audited)
                                                                                  ---------------------       ------------------
<S>                                                                                      <C>                      <C>
Current assets:
     Cash and cash equivalents                                                             $ 3,195,038              $ 3,505,926
     Accounts receivable, net                                                               21,212,028               21,726,062
     Inventories                                                                            18,921,501               16,813,239
     Income taxes receivable                                                                 1,158,849                  752,470
     Deferred income taxes                                                                     931,170                  902,409
     Prepaid expenses and other                                                              1,823,650                1,321,363
                                                                                  ---------------------       ------------------
         Total current assets                                                               47,242,236               45,021,469

Long-term investment, at cost                                                                1,000,000                1,000,000

Property and equipment, at cost                                                             25,848,394               25,196,862
     less accumulated depreciation                                                          (8,997,775)              (7,720,980)
                                                                                  ---------------------       ------------------
                                                                                            16,850,619               17,475,882

Deferred income taxes                                                                        1,120,238                1,120,238

Other assets, net                                                                            2,683,895                2,251,293

Deferred licensing costs, net                                                                1,946,747                2,044,850

Excess of cost over net tangible assets acquired, net                                       32,569,647               33,861,147
                                                                                  ---------------------       ------------------


Total Assets                                                                             $ 103,413,382            $ 102,774,879
                                                                                  =====================       ==================

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
     Current portion of borrowings under bank line of credit agreements                    $ 4,114,926              $ 2,952,307
     Current portion of long-term debt                                                       4,117,520                4,277,598
     Current portion of capital lease obligations                                              656,196                  618,240
     Accounts payable                                                                       10,248,749                9,442,977
     Income taxes payable                                                                       74,755                   74,715
     Accrued salaries and wages                                                              1,655,444                1,346,874
     Deferred income taxes                                                                     400,732                  164,243
     Other accrued liabilities                                                               3,961,982                4,276,554
                                                                                  ---------------------       ------------------
         Total current liabilities                                                          25,230,304               23,153,508


Long-term debt, including borrowings under bank line of credit agreements                   35,359,214               33,150,485
Capital lease obligations                                                                    1,579,682                1,664,165

Deferred income taxes                                                                        2,815,794                3,062,331

Other liabilities                                                                              820,956                  825,592

Shareholders' equity:
     Common stock - authorized 45,000,000 shares and 30,000,000 shares
     at 11/30/2000 and 5/31/2000, respectively, $.10 par value;  issued
     and outstanding 7,277,617 at 11/30/2000 and 7,462,118 at 5/31/2000                       727,762                  746,212
     Additional paid-in capital                                                             15,382,541               16,848,804
     Retained earnings                                                                      27,483,061               28,310,741
     Accumulated other comprehensive loss                                                   (5,985,932)              (4,986,959)
                                                                                  ---------------------       ------------------

         Total shareholders' equity                                                         37,607,432               40,918,798
                                                                                  ---------------------       ------------------

Total Liabilities and Shareholders' equity                                               $ 103,413,382            $ 102,774,879
                                                                                  =====================       ==================
</TABLE>
See accompanying notes.
<PAGE>
<TABLE>
                                                    IMMUCOR, INC.
                                     Condensed Consolidated Statements of Income
                                                     (Unaudited)

<CAPTION>
                                                     Three Months Ended                     Six Months Ended
                                            November 30,       November 30,         November 30,       November 30,
                                                2000               1999                 2000               1999
                                           ----------------   ----------------     ----------------   ----------------

<S>                                            <C>                <C>                  <C>                <C>
Net sales                                      $16,813,264        $20,249,819          $33,894,506        $39,179,786
Cost of sales                                    8,839,249          9,268,872           17,407,203         18,223,299
                                           ----------------   ----------------     ----------------   ----------------
Gross profit                                     7,974,015         10,980,947           16,487,303         20,956,487

Research and development                           528,329            371,569            1,001,354            730,257
Selling and marketing                            3,065,417          2,912,990            6,246,879          5,920,087
Distribution                                     1,411,523          1,463,690            2,839,124          2,998,960
General and administrative                       2,131,915          2,858,310            4,501,825          5,239,288
Amortization expense                               443,661            439,348              927,753            900,248
                                           ----------------   ----------------     ----------------   ----------------
Total operating expenses                         7,580,845          8,045,907           15,516,935         15,788,840
                                           ----------------   ----------------     ----------------   ----------------

Income from operations                             393,170          2,935,040              970,368          5,167,647

Interest income                                     17,238              6,098               21,025             10,615
Interest expense                                  (814,026)          (790,192)          (1,679,741)        (1,439,526)
Other income                                        41,645             60,033              126,946            150,087
                                           ----------------   ----------------     ----------------   ----------------
Total other expense                               (755,143)          (724,061)          (1,531,770)        (1,278,824)
                                           ----------------   ----------------     ----------------   ----------------

(Loss) income before income taxes                 (361,973)         2,210,979             (561,402)         3,888,823

Income taxes                                       250,276            770,934              266,278          1,229,632
                                           ----------------   ----------------     ----------------   ----------------

Net (loss) income                                ($612,249)        $1,440,045            ($827,680)        $2,659,191
                                           ================   ================     ================   ================

(Loss) earnings per share:
   Basic                                            ($0.08)             $0.19               ($0.11)             $0.35
                                           ================   ================     ================   ================

   Diluted                                          ($0.08)             $0.17               ($0.11)             $0.31
                                           ================   ================     ================   ================

Weighted average shares outstanding:
   Basic                                         7,277,617          7,725,678            7,294,709          7,665,335
                                           ================   ================     ================   ================

   Diluted                                       7,277,617          8,627,333            7,294,709          8,692,140
                                           ================   ================     ================   ================

</TABLE>

See accompanying notes.
<PAGE>
<TABLE>
                                                        IMMUCOR, INC.
                                       Condensed Consolidated Statements of Cash Flows
                                                         (Unaudited)
<CAPTION>
                                                                                                  Six Months Ended
                                                                                         November 30,           November 30,
                                                                                             2000                   1999
                                                                                       -----------------      -----------------
<S>                                                                                          <C>                    <C>
OPERATING ACTIVITIES:
  Net (loss) income                                                                           ($827,680)            $2,659,191
  Adjustments to reconcile net (loss) income  to
    net cash (used in) provided by operating activities:
      Depreciation                                                                            1,551,760              1,373,395
      Amortization                                                                              927,753                900,248
      Changes in assets and liabilities:
         Accounts receivable                                                                    514,034             (2,288,361)
         Accounts receivable from former officer and director                                         -                140,946
         Income tax receivable                                                                 (406,415)               180,033
         Inventories                                                                         (2,108,262)            (1,848,289)
         Other current assets                                                                  (988,141)              (247,574)
         Accounts payable                                                                       805,772             (1,070,224)
         Income taxes payable                                                                    25,943                579,568
         Other current liabilities                                                              (10,127)               509,612
                                                                                       -----------------      -----------------

Cash (used in) provided by operating activities                                                (515,363)               888,545

INVESTING ACTIVITIES:
  Purchase of / deposits on property and equipment                                           (1,189,018)            (1,088,497)
  Cash paid for acquisitions                                                                          -               (212,204)
  Acquisition-related severance                                                                       -                (79,019)
  Decrease (increase) in other assets                                                             6,905               (263,337)
                                                                                       -----------------      -----------------


Cash used in investing activities                                                            (1,182,113)            (1,643,057)

FINANCING ACTIVITIES:
  Borrowings/(payments) under line of credit agreements                                       2,640,148               (402,191)
  Payments of long term debt and capitalized leases                                          (2,398,030)              (807,473)
  Borrowings of long term debt and capitalized leases                                         3,191,572                      -
  Exercise of stock options and warrants  (259,131 shares)                                            -              2,062,049
  Purchase and retirement of stock  (184,500 shares)                                         (1,484,713)                     -
                                                                                       -----------------      -----------------

Cash provided by  financing activities                                                        1,948,977                852,385

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                                        (562,389)               102,458
                                                                                       -----------------      -----------------

(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS                                               (310,888)               200,331

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                              3,505,926              2,793,592
                                                                                       -----------------      -----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                   $3,195,038             $2,993,923
                                                                                       =================      =================
</TABLE>
<PAGE>

                                 IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance  with  accounting  principles  generally  accepted in the
United States for interim  financial  information  and the  instructions to Form
10-Q and Article 10 of Regulation S-X.  Accordingly,  they do not include all of
the  information  and  footnotes  required by  accounting  principles  generally
accepted  in the  United  States  for  complete  financial  statements. However,
there has been no material change in the information disclosed in the  Company's
annual financial statements dated May 31, 2000,  except as disclosed  herein. In
the  opinion  of management,  all adjustments  (consisting of  normal  recurring
accruals)  considered necessary  for a fair  presentation  have  been  included.
Operating results  for the  six-month  period ended   November 30, 2000 are  not
necessarily   indicative   of the results  that may be  expected   for the  year
ending  May 31,  2001.   For  further  information,  refer  to the  consolidated
financial  statements and footnotes  thereto included in  the Company's   Annual
Report on Form 10-K for the year ended May 31, 2000.

Certain reclassifications  were made in the  consolidated  financial  statements
for the six-month  period ended November 30, 1999 to conform to the presentation
for the six-month  period ended November 30, 2000.

2.      INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:
<TABLE>
<CAPTION>

                                                      As of                          As of
                                                November 30, 2000                May 31, 2000
                                              ----------------------         ----------------------
<S>                                                     <C>                            <C>
Raw materials and supplies                               $5,713,275                     $4,983,303
Work in process                                           1,298,526                      1,603,117
Finished goods                                           11,909,700                     10,226,819
                                              ----------------------         ----------------------

                                                        $18,921,501                    $16,813,239
                                              ======================         ======================
</TABLE>

3.     EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.
<TABLE>
<CAPTION>

                                                         Three Months Ended                 Six Months Ended
                                                    November 30,     November 30,     November 30,     November 30,
                                                        2000             1999             2000             1999
                                                   ---------------- ---------------  ---------------- ---------------
<S>                                                      <C>             <C>               <C>             <C>
Numerator for basic and diluted earnings per share:
  (Loss) income available to common
           shareholders                                 $(612,249)     $ 1,440,045        $(827,680)      $2,659,191
                                                   ================ ===============  ================ ===============

Denominator:
  For basic (loss) earnings per share - weighted
  average basis                                          7,277,617       7,725,678         7,294,709       7,665,335

  Effect of dilutive stock options and warrants           -                901,655          -              1,026,805
                                                   ---------------- ---------------  ---------------- ---------------
  Denominator for diluted (loss) earnings per share
  adjusted weighted-average shares                       7,277,617       8,627,333         7,294,709       8,692,140
                                                   ================ ===============  ================ ===============

Basic (loss) earnings per share                            $(0.08)           $0.19           $(0.11)           $0.35
                                                   ================ ===============  ================ ===============

Diluted (loss) earnings per share                          $(0.08)           $0.17           $(0.11)           $0.31
                                                   ================ ===============  ================ ===============
</TABLE>

<PAGE>


4.    DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):
<TABLE>
<CAPTION>

                              -------------------------------------------------------------------------------------------
                                                         Three Months Ended November 30, 2000
                              -------------------------------------------------------------------------------------------

                                 U.S.      Germany       Italy       Canada       Other     Eliminations   Consolidated
<S>                            <C>          <C>          <C>         <C>          <C>       <C>                <C>
Net sales:

   Unaffiliated customers      $10,532      $2,090       $1,330      $1,520       $1,341    $      -           $16,813
   Affiliates                    1,778          76            -          26           53       (1,933)             -
                              ----------- -----------  ----------  -----------  ----------  -------------  --------------
      Total                     12,310       2,166        1,330       1,546        1,394       (1,933)          16,813

(Loss) income from operations       39         282          117         361         (347)         (59)             393


                              -------------------------------------------------------------------------------------------
                                                         Three Months Ended November 30, 1999
                              -------------------------------------------------------------------------------------------

                                 U.S.      Germany       Italy       Canada       Other     Eliminations   Consolidated
Net sales:
   Unaffiliated customers      $12,751      $2,757       $1,751      $1,415       $1,576    $     -            $20,250
   Affiliates                    1,731         147            -          80          949       (2,907)             -
                              ----------- -----------  ----------  -----------  ----------  -------------  --------------
      Total                     14,482       2,904        1,751       1,495        2,525       (2,907)          20,250

(Loss) income from operations    2,024         372          168         452          (81)          -             2,935


                              -------------------------------------------------------------------------------------------
                                                          Six Months Ended November 30, 2000
                              -------------------------------------------------------------------------------------------

                                 U.S.      Germany       Italy       Canada       Other     Eliminations   Consolidated
Net sales:
   Unaffiliated customers      $21,192      $4,122       $2,744      $2,761       $3,076    $     -            $33,895
   Affiliates                    3,387         147            -          45           89       (3,668)             -
                              ----------- -----------  ----------  -----------  ----------  -------------  --------------
      Total                     24,579       4,269        2,744       2,806        3,165       (3,668)          33,895

(Loss) income from operations     (329)        647          294         674         (257)         (59)             970

                              -------------------------------------------------------------------------------------------
                                                          Six Months Ended November 30, 1999
                              -------------------------------------------------------------------------------------------

                                 U.S.      Germany       Italy       Canada       Other     Eliminations   Consolidated
Net sales:
   Unaffiliated customers      $24,985      $4,875       $3,419      $2,497       $3,404    $     -            $39,180
   Affiliates                    3,253         248            -         151        1,329       (4,981)             -
                              ----------- -----------  ----------  -----------  ----------  -------------  --------------
      Total                     28,238       5,123        3,419       2,648        4,733       (4,981)          39,180

(Loss) income from operations    3,656         598          330         719         (127)          (8)           5,168
</TABLE>


The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,230,000 and $1,733,000 for the three months ended November 30,
2000 and 1999,  respectively  and  $2,896,000  and $3,481,000 for the six months
ended November 30, 2000 and 1999,  respectively.  The Company's German operation
made net export sales to unaffiliated  customers of  approximately  $170,000 and
$245,000 for the three months ended November 30, 2000 and 1999, respectively and
$387,000  and  $495,000  for the six months  ended  November  30, 2000 and 1999,
respectively.  The  Company's  Canadian  operation  made  net  export  sales  to
unaffiliated  customers  of  approximately  $720,000  and $560,000 for the three
months  ended  November  30,  2000 and 1999,  respectively  and  $1,280,000  and
$1,091,000  for the six months ended  November 30, 2000 and 1999,  respectively.
Product sales to affiliates are valued at market prices.










<PAGE>

5.       COMPREHENSIVE (LOSS) INCOME

The components of comprehensive income for the three-month and six-month periods
ended November 30, 2000 and 1999 are as follows:
<TABLE>
<CAPTION>
                                              Three Months Ended                         Six Months Ended
                                      November 30,         November 30,         November 30,           November 30,
                                          2000                 1999                 2000                   1999
                                     ----------------     ----------------    ------------------     -----------------
<S>                                  <C>                      <C>               <C>                      <C>
Net (loss) income                    $    (612,249)       $   1,440,045         $    (827,680)           $ 2,659,191
Net foreign currency translation          (243,931)            (735,902)             (998,973)              (345,488)
                                     ----------------     ----------------    ------------------     -----------------

Comprehensive (loss) income          $    (856,180)       $     704,143         $  (1,826,653)           $ 2,313,703
                                     ================     ================    ==================     =================
</TABLE>

Accumulated  comprehensive  loss as of  November  30,  2000 and May 31, 2000 was
($5,985,932) and ($4,986,959),  respectively. The balance consists of net losses
on  foreign  currency  translation  adjustments  and has been  disclosed  in the
shareholders' equity section of the condensed consolidated balance sheets.

6.   ACCOUNTS RECEIVABLE FROM OFFICER AND DIRECTOR

On June 6, 2000,  Edward L. Gallup,  President and CEO of Immucor,  Inc. entered
into a loan  agreement  with Immucor,  Inc. to borrow up to $400,000 in order to
meet margin  calls  related to loans made by  brokerage  companies.  The Company
acknowledges  that  certain  benefits  would  accrue to  Immucor,  Inc.  and its
shareholders if such margin calls were satisfied by some means other than having
those shares sold by the broker. The interest rate on the loan is LIBOR plus 2%,
which is the Company's  current  borrowing  rate.  As of November 30, 2000,  the
amount owed to  Immucor,  Inc.  is  $369,000  and is secured by 105,000  Immucor
shares.

7.   CONTINGENCIES

During the quarter ended August 31, 2000,  isolated  performance issues arose at
certain ABS2000 installations that resulted in mistypings not directly affecting
any patient transfusions.  The Company issued a safety notification,  requesting
customers  to  confirm  ABS2000  results  until the cause of the  difficulty  is
identified  and  corrected.  The Company  believes it has identified the factors
that caused the performance issues and submitted this information to the FDA. On
December 6, 2000, with the FDA's approval,  the safety notification for antibody
screening and crossmatch assays was removed. Customers no longer have to perform
manual backup for either of these procedures. In addition to this, the Company's
corrective  action plan for blood  grouping was  accepted by the FDA.  This plan
calls  for the  submission  of a 510(k) to the FDA.  The  Company  expects  this
document  to be filed with the FDA by  February  1, 2001.  At that time  Company
service  engineers will begin the process of completing field corrective  action
on the  ABS2000  and will begin  accumulating  clinical  data for group and type
assays for  selected  customers.  This data will be  collated by the Company and
submitted to the FDA for expedited review. Upon clearance by the FDA, the safety
alert for group and type assays  will be lifted.  These  performance  issues may
result in further  delays in customers  accepting  instruments,  and continue to
affect sales of reagents used in the instruments, and both of these factors will
adversely  impact  sales and  earnings.  The  Company  deferred  recognition  of
instrument  sales of  approximately  $1 million in the first and second quarters
and  believes this is a conservative  approach to  accounting  for sales made in
connection with its third party leasing  arrangement.  In addition,  the Company
may receive  requests for refunds on  instruments  already  placed in service or
requests for financial  concessions  attributable to  inconveniences  associated
with these  performance  issues.  At the date of this report only three  ABS2000
installations  have  requested  credits.  A private label  leasing  company that
finances  customer   purchases of ABS2000  instruments   has advised the Company
that it is not willing to provide  financing  for  additional  purchases of this
instrument until it satisfies itself that the performance  issues related to the
ABS2000 are resolved to the satisfaction of the FDA. The Company is working with
the leasing company to help it obtain the required confirmation from the FDA.
<PAGE>






When the Company  acquired Gamma  Biologicals,  Inc.  ("Gamma  Biologicals")  in
October 1998, Gamma Biologicals was a party to an existing legal proceeding.  On
May 12, 1998, Gamma  Biologicals  received  notification  that a claim of patent
infringement  had  been  filed on that  date in U.S.  District  Court,  Southern
District of Florida,  Miami Division, by Micro Typing Systems, Inc. and Stiftung
fur Diagnostiche Forschung (the Foundation).  Subsequently, in February 1999 the
Company received notification that a second claim was filed in the U.S. District
Court for the  Northern  District of Georgia,  against  Immucor,  Inc. and Gamma
Biologicals for patent  infringement  on the first patent  described above and a
second patent  recently  granted to the  Foundation.  The claim alleges that the
recently  introduced Gamma ReACT Test System infringes U.S. patent No. 5,512,432
granted to the Foundation April 30, 1996 and U.S. patent No.  5,863,802  granted
to the  Foundation on January 26, 1999. The  plaintiffs  seek a preliminary  and
permanent  injunction  against  the  continued  alleged  infringement  by  Gamma
Biologicals and Immucor, and an award of treble damages, with interest and costs
and reasonable  attorney's  fees. On September 5, 2000 a third patent was issued
to the Foundation.  The plaintiffs have asserted infringement of this patent and
are seeking to add this patent to the lawsuit. The Company, in light of this new
patent, is evaluating its position.  A reserve for the lawsuit was recorded with
the acquisition of Gamma Biologicals and management believes it is sufficient to
cover contingent expenses related to the resolution of the lawsuit.

European  results  were  adversely  affected  by  the  interrupted  supply  of a
distributed  product produced by a large multinational  supplier.  The backorder
situation escalated  in the first quarter of fiscal 2001 and reduced sales by an
estimated  $230,000 and by a similar amount in the second  quarter.  The Company
believes that the backorder situation will continue.  (see Part II Item 1. Legal
Proceedings).  The Company expects European results to continue to be suppressed
unless and until this supply problem can be satisfactorily resolved.


<PAGE>
ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations.

    Any  statements   contained   herein  that  are  not  historical   fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 2000.

Financial Condition and Liquidity:

    As of November 30, 2000, the Company's cash position totaled $3,195,000,  an
improvement  of $360,000 for the  quarter.  During the quarter the Company had a
net increase in  borrowings  on long-term  debt and  capitalized  leases of $1.3
million to fund capital improvements  necessary to meet FDA quality requirements
and for inventory  purchases.  For the six-month period, $6.4 million additional
debt was assumed to fund capital improvements, to repay $3.0 million in debt and
to repurchase $1.5 million of the Company's common stock.

     During the first and second  quarters,  the  Company  did not  achieve  the
Fixed Charge Coverage, Funded Debt to EBITDA and  Liquidity  ratios as specified
in its loan  agreement  with its primary  bank.   These  covenant   calculations
deteriorated  due to the Company's recent reported losses.  The bank  has agreed
to waive the present loan covenant defaults  for the  period  ended November 30,
2000, and the Company is finalizing the restructuring of the loan covenants  and
debt repayment schedule.  Management  believes, now that the FDA has lifted  the
ABS2000 safety notification for antibody  screen  and crossmatch, that  the Com-
pany's  current cash   and cash  equivalents, internally   generated funds,  and
amounts available under the  lines of credit  should be  more  than   sufficient
to support operations for planned product introduction and continued improvement
and development of products during the next 12 months.  Management also believes
that should the need arise for additional  capital for other  corporate purposes
that these  needs would be available through the  issuance of various   forms of
equity or debt.

Results of Operations:

Net sales

    Net sales for the three months ended November 30, 2000 totaled  $16,813,000,
a decrease of  $3,437,000  (17%) from last year's  $20,250,000.  The decrease in
sales  was  due,  in  large  part,  to  lower  instrumentation  sales in the U.S
following the ABS2000 safety  notification issued in the first quarter (see Note
7. Contingencies). The Company generated instrument revenues of $930,000 for the
quarter  compared to $3,589,000 for the same period last year.  Customer returns
and the loss of  revenue  for  reagents  provided  free of charge  to  customers
performing  backup testing also reduced  second  quarter sales by  approximately
$591,000.  The  strength  of the US  dollar  versus  the Euro had the  effect of
reducing  reported  European  sales by  approximately  $1,200,000,  or 20%, when
compared to the prior year.  For the six months ended  November  30,  2000,  net
sales were $33,895,000 versus $39,180,000 in the prior year.

Gross profit

    As a percent of sales,  gross profit for the three months ended November 30,
2000 equaled 47.4%  compared to 54.2% for the same period in 1999.  The decrease
in gross profit margin was primarily caused by ABS2000  instrument  installation
costs incurred in this quarter, in advance of revenue  recognition.  The Company
now expects to record these revenues as the  instruments  are accepted.  Further
costs were  incurred for  implementation  of  additional  quality  assurance and
quality  system  policies  to  bring  the  manufacturing   operations  into  FDA
compliance.  Gross profit  for the six  months ended  November  30, 2000 totaled
48.6%  versus 53.5%  for the  same period in 1999.  The Company has  launched an
aggressive reagent price increase that it expects will improve sales and profits
significantly  while only  adding minor increases to the overall cost of patient
care.  It is expected  that this price  increase,  coupled  with new  instrument
placements,  will  return the  Company to  profitability  by the  fiscal  fourth
quarter.
<PAGE>


Operating expenses

    When  compared to the prior year,  research  and  development  costs for the
three and six-month  periods  ended  November 30, 2000   increased  $157,000 and
$271,000  due to  instrument  development  initiatives  for the  Galileo for the
European  market.  The  project is on track for a launch in late  calendar  year
2001.  The  Galileo  is  designed  to  fulfill  the  need in  Europe  for a high
throughput blood serology-testing device with a test menu that includes antibody
screening.

    Selling and marketing expenses for the three and six month periods increased
$152,000 and  $327,000 as compared to the same  periods  last year.  The Company
recorded  $230,000  in  additional  expense   representing  the  impact  of  the
interrupted  reagent  sales  on ABS  customers  who  financed  their  instrument
purchase through fee per use arrangements.

    Distribution  expenses as a percentage of sales have  increased from 7.2% to
8.3% for the fiscal year to date as compared to the prior period, although costs
remained  relatively  constant.  The decrease in sales in the current period was
due primarily to the impact of the ABS2000  safety alert and the strength of the
US dollar.  Neither factor had a significant impact on distribution  activities.
Shipments of core reagent products continued at or above historical levels.

     General and administrative  expenses and amortization expense for the three
and six month  periods  remained relatively  constant, as a percentage of sales,
as compared with the same periods last year.

Interest expense

    When  compared  to the prior  year  three and six  month  periods,  interest
expense  increased  $24,000,  or 3% and $240,000,  or 17%. This is the result of
increased  borrowings on long-term  debt and  capitalized  leases as outlined in
Financial Condition and Liquidity.

Other income

    Other income  decreased  for the three and six month  periods as compared to
the prior year due to foreign currency  transaction  losses  offsetting  foreign
currency transaction gains in the current periods.

Income taxes

    Income tax expense  decreased  during the three and six-month  periods ended
November  30,  2000,  as  compared to the prior  period,  due  primarily  to the
domestic  operating loss that was offset by taxes on income  provided in Germany
and Canada as a result of the Company's  ongoing  implementation of tax planning
strategies.  The domestic  operating losses will offset future domestic earnings
as the Company returns to profitability.


<PAGE>




ITEM 3.  Quantitative and Qualitative Disclosures On Market Risk

There have been no material changes regarding the Company's market risk position
from the  information  provided in its Annual Report on Form 10-K for the fiscal
year ended May 31, 2000. The  quantitative  and  qualitative  disclosures  about
market risk are discussed in Item  7A-Quantitative  and Qualitative  Disclosures
About Market Risk, contained in the Company's Form 10-K.

<PAGE>
                                     Part II
                                OTHER INFORMATION

Item 1. Legal Proceedings.

On December 28, 2000 the Company initiated arbitration against Becton, Dickinson
and Company with the  American  Arbitration  Association  to take place in Santa
Clara County,  California.  The Company's  claims against Becton,  Dickinson and
Company  relate to a  Distributor  Agreement  between the Company and  Biometric
Imaging,  Inc.,  and  Becton,  Dickinson  and  Company  became  a party  to this
agreement  when they  acquired  Biometric  Imaging,  Inc.  in 1999.  The Company
alleges that Becton,  Dickinson and Company either intentionally,  recklessly or
negligently failed to supply medical testing instruments and assay test kits and
either  intentionally,  recklessly or negligently  supplied defective assay test
kits in violation  of its  obligations  under this  Distributor  Agreement.  The
Company  seeks  specific  performance  by Becton,  Dickinson  and Company of the
Distributor Agreement or, in the alternative,  compensatory and punitive damages
in an amount  in  excess  of $4  million.  The  Company  acknowledges  that this
proceeding  is in its initial  stages and  cautions  that it can not  accurately
estimate the amount it may recover, if any.

Item 4.  Submission of Matters to a Vote of Security Holders.

An annual meeting of shareholders was held on November 30, 2000. At the meeting,
the shareholders were asked to approve an amendment to the Company's Articles of
Incorporation to increase the number of authorized shares from 30 million shares
to 45 million  shares.  This  resolution was approved with 6,527,615 votes being
cast in favor of the proposal and 773,263  votes were  withheld or voted against
the proposal and 22,308 shares abstained.

In  addition,  a proposal  to stagger the terms of the board of  directors  into
three classes was not approved.  This  resolution  received  2,495,654  votes in
favor of the  proposal  and  1,611,964  votes were case  against the proposal or
withheld. 38,650 shares abstained and there were 3,176,918 broker non-votes.

Finally, each member of the board was re-elected to the board of directors until
the next annual meeting of shareholders.  Each directors  received the following
number of votes:
<TABLE>
<CAPTION>
                                        For                  Against or Withheld
<S>                                  <C>                           <C>
       Edward L. Gallup              6,439,602                     883,584
       Didier L. Lanson              6,634,832                     688,354
       Dennis M. Smith, Jr. M.D.     6,639,132                     684,054
       Ralph A. Eatz                 6,638,132                     685,054
       G. Bruce Papesh               6,511,968                     811,218
       Joseph E. Rosen               6,636,532                     686,654
       Dr. Gioacchino De Chirico     6,625,932                     697,254
       Daniel T. McKeithan           6,632,132                     691,054
</TABLE>




<PAGE>


Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

         3.1      Amended and Restated Articles of Incorporation

         3.2      Amended and Restated Bylaws.

         4.2      Amendment No. 1 to Shareholders Rights Agreement  dated  as of
                  November  29, 2000  between Immucor, Inc. and  EQUISERVE Trust
                  Company, N.A.

         27       Financial data schedule.

(b) The Company  filed a report on Form 8-K on November 30, 2000  describing  in
Item 9 of such report in accordance with  Regulation FD certain  statements made
by management of the Company at its annual meeting of shareholders.





<PAGE>


                                   SIGNATURES



     Pursuant to the  requirements  of the Securities Exchange Act  of 1934, the
registrant has duly caused this report to be signed on its  behalf by the under-
signed thereunto duly authorized.



                                  IMMUCOR, INC.
                                  (Registrant)



Date:  January 16, 2001








/s/  Edward L. Gallup         Edward L. Gallup, President








/s/  Steven C. Ramsey         Steven C. Ramsey, Senior Vice President - Finance
                                        (Principal Accounting Officer)


<PAGE>